Acentech (United States)

Development of GuaB Inhibitors to Treat Mycobacterium tuberculosis Infection

Abstract Mycobacterium tuberculosis (Mtb) is responsible for more deaths per year than any other infectious disease. Resistance of circulating Mtb to the standard of care treatment regimen is an urgent global health crisis for which novel antibiotic treatments are needed. We have...

Discovery ofHighly Selective Noncovalent MacrocyclicPeptide Inhibitors Suppressing Both TMPRSS2 Protease Activity andViral Receptor Function

Abstract The type II transmembrane serine protease TMPRSS2 plays a critical role in respiratory virus entry, including SARS-CoV-2. Using an mRNA display platform with genetic code reprogramming, we identified macrocyclic peptide (MCP) inhibitors of TMPRSS2 that bound to the TMPRS...